Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 301681
License Grant
Licensor granted Licensee an exclusive license to develop and commercialize Toca 511 & Toca FC within the greater China region, including mainland China, Hong Kong, Macao and Taiwan (the Licensed Territory).
License Property
Toca 511 (vocimagene amiretrorepvec) & Toca FC (extended-release flucytosine) is for the treatment of recurrent high grade glioma (HGG), a brain cancer.
Licensor is a clinical-stage, cancer-selective gene therapy company developing broadly applicable product candidates designed to activate a patient’s immune system against their own cancer.
Field of Use
The products are for use in the treatment of brain cancer. The Licensee is dedicated to developing and commercializing cutting-edge innovative oncology drugs to address the unmet medical needs of cancer patients in China.
IPSCIO Record ID: 186504
License Grant
Licensor granted Licensee the licensed intellectual property covered by the agreement on an exclusive and non-exclusive basis, depending on Licensees use of such intellectual property.
License Property
Licensor agreed to engage Licensee to develop and perform certain in vitro diagnostic assays in connection with the cancer therapy trials of Licensors products concurrently and/or thereafter, to further develop, obtain FDA approval for, and perform one or more of such in vitro diagnostic assays as drug monitoring diagnostics for Licensors products receives marketing approval from the FDA, and following FDA approval of such in vitro diagnostic assay as a monitoring diagnostic, to perform such in vitro diagnostic monitoring assays as necessary in connection with post-marketing clinical trials of Licensors products and, if appropriate, as commercial diagnostic tests.
Licensors products, Toca 511 & Toca FC, are initially for the treatment of recurrent high grade glioma, or HGG, a brain cancer with limited treatment options, low survival rates and, therefore, a significant unmet medical need. Toca 511 is an investigational injectable retroviral replicating vectors or RRV and Toca FC is an investigational small molecule drug.
Field of Use
This agreement is for the drug industry.
IPSCIO Record ID: 319042
License Grant
Licensor and Hong Kong Licensee agreed to collaborate for the development and commercialization of uproleselan and GMI-1687 in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China and to advance the preclinical and clinical development of GMI-1687.
License Property
GMI-1687 is a potential life-cycle extension to uproleselan that has been designed as an innovative antagonist of E-selectin that could be suitable for subcutaneous administration.
Uproleselan is a glycomimetic drug candidate and a specific E-selectin inhibitor that is being developed to be used in combination with chemotherapy to treat patients with acute myeloid leukemia, or AML, a life-threatening hematologic cancer, and potentially other hematologic cancers.
E-selectin plays a critical role in binding cancer cells within vascular niches in the bone marrow, which prevents the cells from entering the circulation where they can be more readily killed by chemotherapy. Glycomimetics are molecules that mimic the structure of carbohydrates involved in biological processes.
Field of Use
The field of use is for the treatment in combination with chemotherapy to treat patients with acute myeloid leukemia (AML) and potentially other hematologic cancers.
IPSCIO Record ID: 276397
License Grant
Licensee obtains rights in mainland China, Hong Kong, Macau and Taiwan to develop and commercialize enoblituzumab.
License Property
Enoblituzumab is an investigational, Fc-optimized mAb that targets B7-H3. MacroGenics recently met with FDA to discuss its plans regarding a Phase 2/3 registration-directed study of enoblituzumab in combination with MGA012 in patients with squamous cell carcinoma of the head and neck (SCCHN).
A clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer.
Field of Use
This agreement pertains to the drug industry.
IPSCIO Record ID: 239202
License Grant
The Licensor entered into an exclusive license agreement with Licensee for the development and commercialization of certain products containing ivosidenib in the forms clinically developed by the Company (Licensed Products) in mainland China, Hong Kong, Macau and Taiwan (the Territory), either as a monotherapy or in combination with other therapies, in all therapeutic uses in humans, excluding brain cancer, unless later added by the Company in its sole discretion (the Field). The Company retains development and commercialization rights with respect to Licensed Products in the rest of the world.
Pursuant to the License Agreement, Licensee will initially be responsible for the development and commercialization of Licensed Products in acute myeloid leukemia (AML) and cholangiocarcinoma in the Territory, as well as other indications that the parties mutually agree to in the future. Licensee will also be responsible, at the Company’s discretion, for the development and commercialization of Licensed Products in brain cancer indications in the Territory. The Company has granted Licensee specified intellectual property licenses to enable Licensee to perform its obligations and exercise its rights under the License Agreement, including license grants to enable Licensee to conduct development and commercialization activities pursuant to the terms of the License Agreement.
License Property
The products are certain products containing ivosidenib in the forms clinically developed by the Company.
Ivosidenib is an experimental drug for treatment of cancer. It is a small molecule inhibitor of IDH1, which is mutated in several forms of cancer.
Field of Use
The Field is in all therapeutic uses in humans, excluding brain cancer, unless later added by the Company in its sole discretion.
IPSCIO Record ID: 267745
License Grant
The Company granted to Chinese Licensee an exclusive license to develop and commercialize the antibody-drug conjugate IMMU-132 (sacituzumab govitecan) (the Product) in the People’s Republic of China, Taiwan, Hong Kong, Macao, Indonesia, Philippines, Vietnam, Thailand, South Korea, Malaysia, Singapore and Mongolia.
License Property
The product ,IMMU-132 (sacituzumab govitecan), relates to a metastatic triple negative breast cancer indication for patients who have received at least 2 prior anti-cancer therapies in a metastatic setting.
Field of Use
This agreement pertains to the drug industry
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
